Clinical examination of heparin-Ca in myocardial infarction patients.
The clinical effect of subcutaneous heparin-Ca of delayed action (Heparin Calcium inj. 25,000 IU/ml, Chemical Works of Gedeon Richter) has been examined in 26 acute and 6 imminent myocardial infarction patients. The therapy was started with 10,000 IU intravenous heparin dose. Subsequently the native blood coagulation time (Lee-White) was continuously maintained on the therapeutic level with subcutaneous injections administered every 12 hours. Except for superficial haemorrhages other side-effects were not observed in any of the cases. Anticoagulant therapy was continued with Syncumar tablet from days 4-5 of acute myocardial infarction.
Páder
K
K
Fourth Department of Internal Medicine, Municipal Bajcsy-Zsilinszky Hospital-Outpatients Clinic.
Kerkovits
G
G
D000328:Adult; D000368:Aged; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D014914:Whole Blood Coagulation Time
C006871:calcium heparin; D006493:Heparin